Precigen, Inc. (PGEN) is a commercial-stage biopharmaceutical company developing precision medicines for immuno-oncology, autoimmune disorders, and infectious diseases. Its proprietary platforms include AdenoVerse immunotherapy and UltraCAR-T. In August 2025, the FDA granted full approval to Papzimeos (zopapogene imadenovec-drba, PRGN-2012) for recurrent respiratory papillomatosis. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. The company leverages gorilla adenovectors, Sleeping Beauty transposon systems, and the UltraPorator electroporation device for gene therapy manufacturing.
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001356090-26-000009 | EDGAR | 81K words |
| 2025-03-19 | 2024-12-31 | 0001356090-25-000007 | EDGAR | 78K words |
| 2024-03-19 | 2023-12-31 | 0001356090-24-000007 | EDGAR | 74K words |
| 2023-03-06 | 2022-12-31 | 0001356090-23-000004 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001356090-22-000002 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001356090-21-000003 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001628280-20-002699 | EDGAR | — |
| 2019-03-01 | 2018-12-31 | 0001356090-19-000004 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001356090-18-000002 | EDGAR | — |
| 2017-03-01 | 2016-12-31 | 0001356090-17-000003 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-04 | 2026-06-30 | 0001356090-26-000030 | EDGAR | 24K words |
| 2025-11-13 | 2025-09-30 | 0001356090-25-000034 | EDGAR | 27K words |
| 2025-08-12 | 2025-06-30 | 0001356090-25-000024 | EDGAR | 23K words |
| 2025-05-14 | 2025-03-31 | 0001356090-25-000019 | EDGAR | 21K words |
| 2024-11-14 | 2024-09-30 | 0001356090-24-000026 | EDGAR | 23K words |
| 2024-08-14 | 2024-06-30 | 0001356090-24-000017 | EDGAR | 22K words |
| 2024-05-14 | 2024-03-31 | 0001356090-24-000010 | EDGAR | 18K words |
| 2023-11-09 | 2023-09-30 | 0001356090-23-000017 | EDGAR | 29K words |
| 2023-08-09 | 2023-06-30 | 0001356090-23-000013 | EDGAR | 29K words |
| 2023-05-10 | 2023-03-31 | 0001356090-23-000009 | EDGAR | 26K words |
| 2022-11-09 | 2022-09-30 | 0001356090-22-000013 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001356090-22-000009 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-04 | 0000950103-26-011876 | EDGAR | 3K words |
| 2026-03-25 | 0000950103-26-004648 | EDGAR | 3K words |
| 2025-11-13 | 0000950103-25-014683 | EDGAR | 4K words |
| 2025-09-17 | 0000950103-25-011775 | EDGAR | 1K words |
| 2025-09-03 | 0001104659-25-086669 | EDGAR | 1K words |
| 2025-08-18 | 0000950103-25-010408 | EDGAR | 22K words |
| 2025-08-18 | 0001104659-25-079497 | EDGAR | 2K words |
| 2025-06-30 | 0000950103-25-008124 | EDGAR | 1K words |
| 2025-05-14 | 0000950103-25-006004 | EDGAR | 3K words |
| 2025-03-19 | 0000950103-25-003637 | EDGAR | 3K words |
229 total filings indexed. 197 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001356090 |
| Ticker | PGEN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | VA |
| Headquarters | Germantown, Maryland |
| Website | http://www.precigen.com |
| Listed | 2013-08-08 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PGEN (~200 tokens, structured JSON with cryptographic provenance)